Thymalin is often presented as a simple 'thymus peptide.' It is instead a tissue-derived polypeptide complex, which makes it fundamentally different from a single defined molecule such as thymosin alpha 1. Published studies include experimental work and small or older clinical reports, not a modern approval-grade evidence base for immune or longevity use.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Polypeptide complex isolated from thymus tissue, not one defined single peptide · also sold as thymus peptide complex, thymic extract
Thymosin alpha 1 is a defined 28-amino-acid peptide. Thymalin is described in the literature as a polypeptide complex isolated from thymus tissue. Treating them as synonyms erases the differences in composition, manufacturing, pharmacology, and evidence.
That distinction is particularly important for injections. A paper studying a particular tissue-derived preparation cannot establish the identity or clinical performance of every product sold under a similar name.
| What's cited | Range |
|---|---|
| Established US clinical dose | None |
No FDA-approved Thymalin dosage exists in the US. Published reports and product protocols use heterogeneous preparations and indications, so they cannot establish a general immune, anti-aging, or self-injection regimen.
| Signal | Frequency | Context |
|---|---|---|
| Human adverse-event profile | unknown / not studied | The available literature does not provide a modern, large controlled safety dataset for wellness use. |
| Batch-to-batch compositional variation | unknown / not studied | A tissue-derived polypeptide complex is not equivalent to a single defined synthetic active ingredient. |
Check the exact molecule, preparation, and trial before relying on a claim.